Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus Doxorubicin in Advanced Soft Tissue Sarcomas
NCT03042819Phase 1Completed
- Sponsor
- University Health Network
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in soft tissue sarcoma (STS), sponsored by University Health Network. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 3 years and Recommended Phase II Dose at 3 years. Started May 2017; status: completed.
02
Drugs
selinexor
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03042819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042819.